DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

Carrot today announced a partnership with URA, the world's leading smart ring, and Dexcom, the global leader in glucose biosensing, to empower members with actionable, personalized insights that ...

DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant ...

The deal concerns the connectivity between Glooko's self-titled mobile app and Dexcom's continuous glucose monitoring (CGM) devices. Currently, Dexcom device users upload CGM data to the Glooko app ...

PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed.